| Autor: |
TIBBEN, J. G., MASSUGER, L. F.A.G., CLAESSENS, R. A.M.J., SCHIJF, C. P.T., PAK, K. Y., STRIJK, S. P., KENEMANS, P., CORSTENS, F. H.M. |
| Zdroj: |
Nuclear Medicine Communications; December 1992, Vol. 13 Issue: 12 |
| Abstrakt: |
Fab' fragments of the monoclonal antibody OV-TL 3, that recognizes an ovarian carcinoma-associated antigen (OA3), were labelled with 99Tcmusing D-glucarate as a ligand. Twenty patients suspected of having primary or recurrent ovarian cancer received intravenously 1 mg of the Fab' labelled with 740 MBq 99Tcm. Both planar and single photon emission computed tomographic (SPECT) scintigraphy were performed up to 30 h after intravenous infusion. In 19 out of 20 patients surgical and histopathological evaluation was performed between 2 and 6 days postinfusion. Imaging results were compared with X-ray computed tomography (CT), ultrasonography (US) and CA 125 serum level. Blood clearance was fast with median t1/2β of 9.5 h. Thirty-seven per cent of the injected dose ( ID) was excreted in the urine within the first 24 h, whereas 7 ID was excreted in the 24 h faeces. In one patient with an OA3 negative ovarian carcinoma, radioimmunoscintigraphy (RIS) did not visualize the tumour. In two other patients a benign ovarian cyst was found, also showing no elevated uptake. In 13 out of 17 patients ovarian cancer lesions were detected with RIS, whereas CT and US detected lesions in, respectively, 15 and 12 patients. Of 36 surgically defined tumour deposits larger than 1 cm in diameter, 53 were detected and localized with RIS, whereas CT and US detected 61 and 40, respectively. Radioimmunoscintigraphy with 99Tcm-OV-TL 3 Fab' is less distressing for the patients but the overall imaging performance is not improved when compared with 111In-OV-TL 3 F(ab′)2. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
